Orna Therapeutics, Inc.

Biopharma merger and acquisition value for the first quarter of 2025 reached $38.4bn from 41 transactions, 22 of which had disclosed values. Making up almost 38% of that total was Johnson & Johnso

In the top alliance by deal value, Orna Therapeutics (through its ReNAgade Therapeutics subsidiary) entered a three-year research collaboration with Vertex Pharmaceuticals designed to use Orna’s novel

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Partners With UK’s Alchemab On A

The reason Erik Wiklund can so clearly recall the evolution of the science of circular RNA is that he was there from the outset. “In the late 2000s, during my PhD work in molecular biology, Thomas Han